AUTHORS
Mathieu Leclerc, PhD, Ludovic Jondreville, MD, PhD2, Martin Carre, MD3, Hunault-Berger Mathilde, MD, PhD4, Jean Baptiste Mear, MD5, Hélène Labussière-Wallet, MD6, Bruno Lioure, MD7, Felipe Suarez, MD, PhD8, Patrice Chevallier, MD, PhD9, Anne Menard10, Nicolas Vallet, MD, PhD11, Sylvain Chantepie, MD12, Marie-Anne Couturier, MD13, Etienne Daguindau14, Anne Huynh, MD15, Michael Loschi, MD, PhD16, Pascal Turlure17, Patrice Ceballos, MD18, Arnaud Pigneux, MD, PhD19, Christian Recher, MD, PhD20, Herve Dombret Sr, MD21, Gerard Socie, MD, PhD22, Edouard Forcade, MD, PhD23, Regis Peffault De Latour, MD, PhD24
AFFILIATIONS
1 Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
2 Hôpital Necker Enfants Malades, Assistance Publique - Hôpitaux de Paris, PARIS, France
3 CHU de Grenoble, Grenoble, France
4 CHU d'Angers, INSERM CRCI2NA, FHU Goal, Angers, France
5 CHU de Rennes, Rennes, France
6 Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France
7 CHU de Strasbourg, Strasbourg, France
8 Hôpital Necker Enfants Malades, Assistance Publique - Hôpitaux de Paris, PARIS, France
9 CHU de Nantes, Nantes, France
10 Centre Henri-Becquerel, Rouen, France
11 CHU de Tours, Tours, France
12 CHU de Caen, Caen, France
13 CHU de Brest, Brest, France
14 CHU de Besançon, Besançon, France
15 IUCT Oncopôle, CHU de Toulouse, Toulouse, France
16 CHU de Nice, Nice, France
17 CHU de Limoges, Limoges, France
18 CHU de Montpellier, Montpellier, France
19 Hôpital Haut Lévêque, CHU de Bordeaux, Pessac, France
20 IUCT Oncopôle, CHU de Toulouse, Toulouse, France
21 Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France
22 Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France
23 Hôpital Haut Lévêque, CHU de Bordeaux, Pessac, France
24 Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, PARIS, France
ABSTRACT
Introduction
CsA+MTX is considered a standard for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic stem cell transplantation (allo-HSCT), after myeloablative conditioning regimen (MAC). However, no randomized trial ever compared CsA+MTX versus CsA + MMF in this setting.
Methods
The French Backbone Intergroup (BIG-1) trial (NCT02416388) was a large open label, multicenter phase II/III study in patients (pts) aged 18-60 years (yrs) with newly diagnosed acute myeloid leukemia (AML). Patient risks were classified upon cytogenetics and molecular biology according to protocol definition (different from ELN). Post hoc analysis included extensive molecular analysis to characterize pts according to ELN-2022 classification. After complete remission (CR), pts with intermediate risk AML were considered for a MAC regimen if age < 45 yrs and HCT-CI ≤ 2. Pts with a 10/10 matched donor (related – MRD - or unrelated – MUD -) were eligible for the R3MAC sub-study. MAC regimen consisted of busulfan 3.2 mg/kg/d from day -7 (D-7) to D-4 and cyclophosphamide 60 mg/kg/d at D-3 and D-2 (Bu-Cy). Anti-thymocyte globulin (ATG) 2.5 mg/kg/d at D-3 and D-2 was recommended for MUD allo-HSCT. Pts were randomized 1:1 to receive either CsA+MTX (reference group) or CsA+MMF, and were stratified according to induction regimen (idarubicin or daunorubicin) and donor type (MRD or MUD). MTX was given at 15 mg/m2 at D+1 and 10mg/m2 at D+3, D+6, D+11. MMF was given at 15 mg/kg BID from D0 to D+28 for MRD or +45 for MUD. The primary endpoint was day 100 (D+100) cumulative incidence (CI) of grade II-IV acute GVHD (aGVHD), with an expected reduction of 15% of CI grade II-IV aGVHD in the CSA+MMF arm. With 80% power and a 2-sided alpha-risk of 5%, a total of 346 pts was estimated. Secondary endpoints included CI of grade III-IV aGVHD, chronic GVHD (cGVHD), 1-year non-relapse mortality (NRM), relapse incidence (RI) and overall survival (OS).
Results
Due to low accrual rate, inclusions in the R3MAC sub-study were prematurely closed on March 2018. At that time, a total of 48 pts had been included and randomized (24 in each arm). One patient in each randomization arm did not proceed to transplant, one because of disease relapse (CsA+MMF arm), the other because of the late identification of a bi-allelic CEBPA mutation (CsA+MTX arm). Median age was 36 yrs, and 28 pts (61%) were male. Donors were MRD in 20 cases (43%) and MUD in 26 cases (57%). PBSCs were used in the majority of cases (57%). In addition to the randomized GVHD prophylaxis, 25 pts also received ATG (12 in the CsA+MTX group and 13 in the CsA+MMF group).
Median follow-up (FU) for the whole cohort was 82.3 months. Forty-six percent of pts developed grade II-IV aGVHD at D+100, including 13% with grade III-IV. Incidence of grade II-IV aGVHD at D+100 did not differ between treatment arms: 44% in the CsA+MTX arm versus 48% in the CsA+MMF arm (P=0.77). There was also no significant difference when focusing on grade III-IV aGVHD (13% in each arm), chronic GVHD (30% and 39% at 1 and 3 yrs in the CsA+MTX arm versus 35% and 57% in the CsA+MMF arm) and moderate/severe cGVHD (22% and 26% versus 22% and 39%).
OS was 89%, and 83% at 1, and 5 yrs post-transplant respectively, with corresponding RI of 15%, and 26%, NRM rates of 4%, and 7%, and relapse-free survival (RFS) rates of 80%, and 67%. NRM was similar between treatment arms: 4% at 1 year and 9% at 3 yrs in the CsA+MTX arm versus 4% at 1 and 3 yrs in the CsA+MMF arm (P=0.6). We identified more pts with high-risk AML in the standard CSA+MTX arm according to ELN-2022 classification (65% versus 22% in the CsA+MMF arm, P=0.006), which might explain the higher relapse incidence observed in the CsA+MTX arm at 3 yrs (39% versus 13%, P=0.04), although there was no significant difference at the pre-specified 1-year timepoint, resulting in a worse RFS (52% versus 83% at 3 yrs, P=0.02) and a numerically lower OS (74% versus 91% at 3 yrs, P=0.11).
Conclusions
This study failed to significantly reduce grade II-IV aGVHD incidence between standard CsA+MTX versus CsA+MMF in CR1 intermediate-risk AML pts receiving a Bu-Cy regimen because of early termination due to low accrual. With more than 6 yrs of median FU, this study however showed excellent results in terms of OS and NRM (83% and 7% at 5 yrs respectively).
DISCLOSURES
Mathieu Leclerc, PhD: No relevant conflicts of interest to declare.